Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models
The diabetes and obesity epidemics are increasing the incidence of stroke, and consequently the need for treatments to improve stroke outcome. Our results indicate that clinically used type 2 diabetes treatments could be employed in a preventive role to improve stroke outcome by exerting dual pharmacological action: weight loss and acute neuroprotection. These findings could have novel therapeutic implications for many people.
Authors
- Thomas Nyström (ORCID: https://orcid.org/0000-0002-3462-7990)
- Ellen Vercalsteren (ORCID: https://orcid.org/0000-0002-9425-4209)
- Katherin Bleymehl (ORCID: https://orcid.org/0009-0007-6269-1061)
- Thomas Klein (ORCID: https://orcid.org/0000-0001-5762-9166)
- Mihaela Oana Romanitan (ORCID: https://orcid.org/0009-0001-4719-6624)
- Peter Haebel
- Vladimer Darsalia (ORCID: https://orcid.org/0000-0002-6693-934X)
- Dimitra Karampatsi (ORCID: https://orcid.org/0000-0002-5316-088X)
- Cesare Patrone (ORCID: https://orcid.org/0000-0003-0470-4606)
- Mihaela Neicu
Institutions
- Boehringer Ingelheim (Germany) (DE)
- Karolinska Institutet (SE)
- Stockholm South General Hospital (SE)
Publication Details
- Journal
- Diabetologia
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1007/s00125-025-06567-4
- Citations
- 1
- Primary Topic
- Regulation of Appetite and Obesity
- Type
- article
- Field-Weighted Citation Impact
- 0.91
Funders
- Karolinska Institutet